Gefapixant effective option for uncontrolled chronic cough, finds study

Inclusion Criteria were:

• Chest radiograph or computed tomography scan of the thorax (within 5 years of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator

• Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough or unexplained chronic cough

• Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance

• Provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires)

The primary endpoint was 12-week Awake Objective Cough Frequency, with secondary endpoints including various measures of cough severity and quality of life: the 7-item Cough Severity Diary (CSD), the participant-rated Patient Global Impression of Change (PGIC), and the 19-item Leicester Cough Questionnaire (LCQ).

Improvements in [patient reported outcomes] in this trial are consistent with data on objective cough frequency reductions and indicate benefits related to the quality of life," the researchers concluded.

For further reading click on the following,

Clinical Trials